Description
Join us for 'The HPV Puzzle: Interpreting Positivity and Protecting the Future,' an insightful session exploring the nuances of HPV testing and its implications for health. Learn how to accurately interpret HPV results, understand risk factors, and implement preventive strategies. Our experts will discuss vaccination, screening guidelines, and ways to protect yourself and loved ones from HPV-related complications. This webinar is designed for anyone seeking clarity on HPV and proactive steps toward long-term health. Don’t miss this opportunity to empower yourself with knowledge and prevention."
Summary Listen
- HPV is a common infection, with types 16 and 18 strongly linked to cervical cancer, accounting for over 70% of cases. Transmission typically occurs through sexual contact or skin-to-skin contact. Many infections are asymptomatic, but symptoms can include genital warts and itching. Most individuals will contract HPV in their lifetime, often in their teens and early twenties.
- Screening for HPV and cervical cancer involves acetic acid application, Pap tests, and DNA tests. Pap tests analyze cervical cells for abnormalities, while HPV DNA tests identify specific high-risk strains. Co-testing combines both Pap and HPV tests in a single sample. Currently, there are no standard HPV tests for males.
- Screening guidelines recommend starting at age 21 with Pap tests every three years. For ages 30-65, HPV testing every five years, co-testing, or Pap tests every three years are advised. After 65, screening can cease if prior results are normal. Vaccination history and previous abnormal results influence screening frequency. Indian guidelines recommend starting screening at 25 or 30, depending on resource availability, using HPV testing, cytology, co-testing, or VIA.
- A positive HPV test indicates an increased risk of cervical changes, necessitating further evaluation. Genotype information, particularly for HPV 16 and 18, is crucial for management. Management may include watchful waiting, frequent check-ups, or biopsies. In many cases, the immune system clears HPV infections within one to two years.
- HPV vaccination is recommended for individuals aged 11-12 and can start at 9. A two-dose series is recommended for those starting before 15, while a three-dose series is advised for those starting later or who are immunocompromised. Adults up to age 45 should discuss vaccination with their doctor, and those 46 and older may not benefit significantly. Contraindications include allergic reactions and acute illness.
- HPV positivity does not equate to cancer, rather it indicates risk. Screening and vaccination are complementary preventive measures. Prevention works best when started early, but benefits extend beyond adolescence. Pro-vaccination guidance is acceptable as long as the healthcare provider is well informed to be able to guide the patients.
Sample Certificate
About the Speakers
Dr. Sheetal Sachdeva
Senior Consultant Gynaecologist and Obstetrician, Cloudnine Group of Hospitals, Delhi
Comments
Comments
You must be logged in to leave a comment.